Novel Agents Ease Chemotherapy Burden in ALL But Treating Older Patients Remains a Challenge

Novel Agents Ease Chemotherapy Burden in ALL, But Treating Older Patients Remains a Challenge

Immune-based approaches have revolutionized the treatment of acute lymphoblastic lymphoma, especially for patients unable to tolerate multiagent chemotherapy. Now, investigators are looking forward to seeing these agents move into frontline settings, perhaps leading to chemotherapy-free approaches.

More From BioPortfolio on "Novel Agents Ease Chemotherapy Burden in ALL, But Treating Older Patients Remains a Challenge"